ERX-315

N/A

Report date: 2024/08/23 20:00:42
NME

Base Information

Drug NameERX-315
Drug Alias NameERX-315
ClassificationSmall molecules
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursEndometrial Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesEtirarx LLC
China Registration ClassN/A

Develop Information

Active CompaniesEtiraRx Australia Pty LtdEtirarx LLC
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursEndometrial Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A